IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.263
+0.001 (0.42%)
At close: Jun 26, 2026, 4:00 PM EDT
0.272
+0.009 (3.50%)
Pre-market: Jun 29, 2026, 8:04 AM EDT
IGC Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for IGC Pharma stock has a target of 5.50, which predicts an increase of 1,991.25% from the current stock price of 0.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IGC Pharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Dec '25 | Feb '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant | Ascendiant | Buy Maintains $5.25 → $5.5 | Buy | Maintains | $5.25 → $5.5 | +1,991.25% | Jun 5, 2026 |
Financial Forecast
Revenue This Year
857.00K
from 1.27M
Decreased by -32.57%
Revenue Next Year
1.03M
from 857.00K
Increased by 20.01%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.09
from -0.09
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 857,000 | 1.2M |
| Avg | 857,000 | 1.0M |
| Low | 857,000 | 857,000 |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | -32.6% | 40.0% |
| Avg | -32.6% | 20.0% |
| Low | -32.6% | - |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.09 | -0.08 |
| Avg | -0.09 | -0.09 |
| Low | -0.09 | -0.09 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.